CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Research & Development News Teva's Oral MS Drug Data Disappoints the Analysts
News
13 Apr 2011

Teva's Oral MS Drug Data Disappoints the Analysts

Compared to a placebo, the drug cut the rate of relapses by 23 percent. Investigators also noted that the drug group demonstrated an average drop in the progression of disability by 36 percent.

Teva's oral MS drug laquinimod cut relapses at a lower rate than standard injectable therapies on the market.

 

Compared to a placebo, the drug cut the rate of relapses by 23 percent. But analysts had been expecting somewhat better results, which debut as Novartis is marketing its own new MS pill, Gilenya, and Biogen Idec has reported a successful conclusion for the Phase III study of its experimental MS drug. Investigators also noted that the drug group demonstrated an average drop in the progression of disability by 36 percent.
Related tags
Research & Development

Related News